Welcome to our dedicated page for COMPUGEN SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on COMPUGEN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into COMPUGEN's regulatory disclosures and financial reporting.
Compugen Ltd. filed a report describing the appointment of Michele Holcomb, Ph.D. as a new independent director to its Board, effective February 11, 2026. She will serve until immediately after the 2026 annual general meeting or until a successor is elected or her office is vacated earlier.
The company highlights Dr. Holcomb’s more than 30 years of experience across biotech, pharmaceuticals, and healthcare services, including senior roles at Cardinal Health, Teva Pharmaceuticals, and McKinsey & Company, as well as current board positions at PureTech Health, Kimball Electronics, and Controlant.
Compugen Ltd. entered into an amendment with MedImmune Limited, part of the AstraZeneca Group, under which it sold to AstraZeneca a portion of its existing royalty interest in the cancer immunotherapy candidate rilvegostomig for a $65 million upfront payment, due within five business days of the December 16, 2025 amendment date.
The amendment also increases by $25 million the milestone payment payable to Compugen upon the next milestone, defined as the first acceptance of the Biologics License Application for rilvegostomig.
This transaction shifts part of Compugen’s expected future royalty stream into near-term cash while enhancing the potential size of a key future regulatory milestone payment linked to BLA acceptance.
Compugen Ltd. (CGEN) filed a Form 6-K stating it furnished a press release with the company’s third quarter 2025 results as Exhibit 99.1. The filing notes that, with the exception of quotes attributed to Eran Ophir, Ph.D., the press release is incorporated by reference into the company’s effective Form F-3 registration statement (File No. 333-270985).
The report was signed by Eran Ben Dor, General Counsel, on November 10, 2025. Investors seeking financial details should refer to Exhibit 99.1, which contains the full Q3 2025 results.
Compugen Ltd. (CGEN) filed a Form 6-K noting it issued a press release on October 13, 2025, which is furnished as Exhibit 99.1. With the exception of the third, fourth, and fifth paragraphs of the press release, the information incorporated by reference in this report is also incorporated into the Company’s Registration Statement on Form F-3 (File No. 333-270985).
The report was signed by Eran Ben Dor, General Counsel, on October 14, 2025.
Compugen Ltd. reports that it held its 2025 Annual General Meeting of Shareholders on September 16, 2025. According to the company, all proposals presented to shareholders at the meeting were approved by the required majority, meaning each item on the agenda received sufficient support to pass. The notice of meeting, proxy statement and proxy card had previously been filed with the SEC and are incorporated by reference. The company also states that the information in this report is incorporated by reference into its existing shelf registration statement on Form F-3.